Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake

Andrews, 2010 Aslett, 2010, TriTrypDB: a functional genomic resource for the Trypanosomatidae, Nucleic Acids Res., 38, D457, 10.1093/nar/gkp851 Banuls, 2007, Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans, Adv. Parasitol., 64, 1, 10.1016/S0065-308X(06)64001-3 Benjamini, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J. Roy. Stat. Soc. B, 57, 289 Bhandari, 2012, Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis, PLoS Neglected Trop. Dis., 6, 10.1371/journal.pntd.0001657 Burza, 2018, Leishmaniasis, Lancet, 392, 951, 10.1016/S0140-6736(18)31204-2 Chrusciak-Talhari, 2011, Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil, Am. J. Trop. Med. Hyg., 84, 255, 10.4269/ajtmh.2011.10-0155 Coelho, 2012, Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing, PLoS Neglected Trop. Dis., 6, 10.1371/journal.pntd.0001512 Coelho, 2014, In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis, PLoS Neglected Trop. Dis., 8, 10.1371/journal.pntd.0002999 Cojean, 2012, Leishmania resistance to miltefosine associated with genetic marker, Emerg. Infect. Dis., 18, 704, 10.3201/eid1804.110841 Deep, 2017, Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress, PLoS Neglected Trop. Dis., 11, 10.1371/journal.pntd.0005641 Espada, 2017, Susceptibility to miltefosine in Brazilian clinical isolates of Leishmania (Viannia) braziliensis, Am. J. Trop. Med. Hyg., 96, 656 Fernandez-Prada, 2016, Different mutations in a P-type ATPase transporter in Leishmania parasites are associated with cross-resistance to two leading drugs by distinct mechanisms, PLoS Neglected Trop. Dis., 10, 10.1371/journal.pntd.0005171 Grimaldi, 1989, A review of the geographic distribution and epidemiology of leishmaniasis in the New World, Am. J. Trop. Med. Hyg., 41, 687, 10.4269/ajtmh.1989.41.687 Hefnawy, 2017, Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs, Trends Parasitol., 33, 162, 10.1016/j.pt.2016.11.003 Hendrickx, 2015, Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome, J. Antimicrob. Chemother., 70, 3023, 10.1093/jac/dkv237 Hornillos, 2008, Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal activity, as fluorescent analogues of miltefosine, Bioorg. Med. Chem. Lett, 18, 6336, 10.1016/j.bmcl.2008.10.089 Koressaar, 2007, Enhancements and modifications of primer design program Primer3, Bioinformatics, 23, 1289, 10.1093/bioinformatics/btm091 Kumar, 2009, In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity, Antimicrob. Agents Chemother., 53, 835, 10.1128/AAC.01233-08 Laffitte, 2016, Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance, Parasitol. Res., 115, 3699, 10.1007/s00436-016-5195-y Laffitte, 2016, Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance, F1000Research, 5, 2350, 10.12688/f1000research.9218.1 Langmead, 2012, Fast gapped-read alignment with Bowtie 2, Nat. Methods, 9, 357, 10.1038/nmeth.1923 Law, 2016, 5 Li, 2009, The sequence alignment/map format and SAMtools, Bioinformatics, 25, 2078, 10.1093/bioinformatics/btp352 Liao, 2014, featureCounts: an efficient general purpose program for assigning sequence reads to genomic features, Bioinformatics, 30, 923, 10.1093/bioinformatics/btt656 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods (San Diego, Calif.), 25, 402, 10.1006/meth.2001.1262 Luque-Ortega, 2007, Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes, Antimicrob. Agents Chemother., 51, 1327, 10.1128/AAC.01415-06 Machado, 2010, Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial, PLoS Neglected Trop. Dis., 4, 10.1371/journal.pntd.0000912 Martin, 2011, Cutadapt removes adapter sequences from high-throughput sequencing reads, EMBnet.journal, 17, 10, 10.14806/ej.17.1.200 Mondelaers, 2018, Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility, J. Antimicrob. Chemother., 73, 392, 10.1093/jac/dkx407 Mondelaers, 2016, Genomic and molecular characterization of miltefosine resistance in Leishmania infantum strains with either natural or acquired resistance through experimental selection of intracellular amastigotes, PLoS One, 11, 10.1371/journal.pone.0154101 Obonaga, 2014, Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species, Antimicrob. Agents Chemother., 58, 144, 10.1128/AAC.01023-13 Perez-Victoria, 2003, Leishmania donovani resistance to miltefosine involves a defective inward translocation od the drug, Antimicrob. Agents Chemother., 47, 2397, 10.1128/AAC.47.8.2397-2403.2003 Perez-Victoria, 2003, Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance, J. Biol. Chem., 278, 49965 Perez-Victoria, 2006, Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites, J. Biol. Chem., 281, 23766, 10.1074/jbc.M605214200 Perez-Victoria, 2006, Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux, Antimicrob. Agents Chemother., 50, 3102, 10.1128/AAC.00423-06 Prajapati, 2013, In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis, Am. J. Trop. Med. Hyg., 89, 750, 10.4269/ajtmh.13-0096 Rakotomanga, 2007, Miltefosine affects lipid metabolism in Leishmania donovani promastigotes, Antimicrob. Agents Chemother., 51, 1425, 10.1128/AAC.01123-06 Ritchie, 2015, Limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43, e47, 10.1093/nar/gkv007 Rozen, 2000, Primer3 on the WWW for general users and for biologist programmers, Methods Mol. Biol., 132, 365 Sanchez-Canete, 2009, Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug, Antimicrob. Agents Chemother., 53, 1305, 10.1128/AAC.01694-08 Santa-Rita, 2004, Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis, J. Antimicrob. Chemother., 54, 704, 10.1093/jac/dkh380 Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nat. Methods, 9, 676, 10.1038/nmeth.2019 Seifert, 2007, Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo, Int. J. Antimicrob. Agents, 30, 229, 10.1016/j.ijantimicag.2007.05.007 Shaw, 2016, In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization, Mol. Microbiol., 99, 1134, 10.1111/mmi.13291 Srivastava, 2017, Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India, Parasites Vectors, 10, 49, 10.1186/s13071-017-1969-z Sunyoto, 2018, Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most, BMJ global health, 3, 10.1136/bmjgh-2018-000709 Utaile, 2013, Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model, Exp. Parasitol., 134, 68, 10.1016/j.exppara.2013.01.022 Vacchina, 2016, Genomic appraisal of the multifactorial basis for in vitro acquisition of miltefosine resistance in Leishmania donovani, Antimicrob. Agents Chemother., 60, 4089, 10.1128/AAC.00478-16 Weckx, 2005, novoSNP, a novel computational tool for sequence variation discovery, Genome Res., 15, 436, 10.1101/gr.2754005 Weingartner, 2010, Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasion, PLoS One, 5, 10.1371/journal.pone.0012443 WHO, 2018 Yardley, 2005, The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine, Am. J. Trop. Med. Hyg., 73, 272, 10.4269/ajtmh.2005.73.272 Zauli-Nascimento, 2010, In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B, Trop. Med. Int. Health, 15, 68